Would you extrapolate IMPower010 data to offer adjuvant atezolizumab to a patient with N2 PDL1-high (>50%) NSCLC who had been treated with induction chemotherapy followed by definitive R0 resection after partial response?

As outlined by Dr. @Dr. First Last, IMpower010 did not enroll patients who had received neoadjuvant chemotherapy and I fully agree that neoadjuvant chemotherapy + immunotherapy trial would be appealing in patients with N2 disease. Especially, since treatment of these patients is controversial and ch...

The IMpower010 study did not enroll patients with N2 disease undergoing neoadjuvant chemotherapy followed by an R0 resection. I agree the biologic concept of using adjuvant atezolizumab in patients with completely resected disease who were treated with neoadjuvant systemic chemotherapy is a similar ...